Xilong Scientific Co., Ltd.
SZSE:002584.SZ
5.61 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 7,693.247 | 6,183.209 | 6,837.668 | 6,243.171 | 3,337.662 | 3,355.078 | 3,394.99 | 2,928.384 | 2,513.529 | 2,197.936 | 2,239.893 | 1,544.721 | 1,281.031 | 1,164.155 | 881.978 | 766.705 |
| Cost of Revenue
| 7,223.167 | 5,741.708 | 6,280.249 | 5,763.719 | 2,805.586 | 2,817.609 | 2,934.248 | 2,490.502 | 2,094.453 | 1,823.533 | 1,973.192 | 1,295.912 | 1,045.082 | 951.528 | 721.219 | 627.727 |
| Gross Profit
| 470.08 | 441.501 | 557.419 | 479.452 | 532.076 | 537.47 | 460.742 | 437.881 | 419.076 | 374.402 | 266.701 | 248.809 | 235.949 | 212.627 | 160.759 | 138.978 |
| Gross Profit Ratio
| 0.061 | 0.071 | 0.082 | 0.077 | 0.159 | 0.16 | 0.136 | 0.15 | 0.167 | 0.17 | 0.119 | 0.161 | 0.184 | 0.183 | 0.182 | 0.181 |
| Reseach & Development Expenses
| 95.701 | 90.467 | 118.969 | 102.719 | 87.58 | 81.745 | 59.219 | 40.275 | 36.837 | 32.717 | 25.165 | 12.723 | 9.872 | 7.609 | 4.552 | 4.451 |
| General & Administrative Expenses
| 48.608 | 29.45 | 49.762 | 41.32 | 29.304 | 38.347 | 39.474 | 34.578 | 32.667 | 36.593 | 29.69 | 25.08 | 20.079 | 17.913 | 11.788 | 15.744 |
| Selling & Marketing Expenses
| 103.803 | 101.432 | 108.632 | 120.167 | 183.125 | 182.984 | 156.488 | 143.768 | 131.23 | 133.912 | 100.03 | 97.83 | 75.977 | 66.731 | 49.53 | 39.233 |
| SG&A
| 152.411 | 130.882 | 158.394 | 161.487 | 212.429 | 221.331 | 195.962 | 178.346 | 163.897 | 170.505 | 129.72 | 122.91 | 96.056 | 84.644 | 61.318 | 54.977 |
| Other Expenses
| -3.086 | 92.035 | 85.84 | 87.617 | 96.536 | -0.646 | -5.135 | 6.515 | 5.464 | 8.615 | 7.331 | 10.078 | 8.448 | 6.251 | 4.95 | 1.469 |
| Operating Expenses
| 325.392 | 313.384 | 363.203 | 351.824 | 396.546 | 392.605 | 354.752 | 324.09 | 278.95 | 260.52 | 201.443 | 173.957 | 138.515 | 122.365 | 90.356 | 78.666 |
| Operating Income
| 46.01 | 190.504 | 334.084 | 146.815 | 125.595 | 69.537 | 104.894 | 105.1 | 116.039 | 91.403 | 52.226 | 67.609 | 89.554 | 84.677 | 62.755 | 53.539 |
| Operating Income Ratio
| 0.006 | 0.031 | 0.049 | 0.024 | 0.038 | 0.021 | 0.031 | 0.036 | 0.046 | 0.042 | 0.023 | 0.044 | 0.07 | 0.073 | 0.071 | 0.07 |
| Total Other Income Expenses Net
| -3.086 | -87.769 | -106.832 | -65.569 | -79.398 | -75.974 | -6.231 | -3.152 | -19.373 | -14.649 | -6.744 | 2.795 | 0.423 | -1.5 | -2.755 | -5.32 |
| Income Before Tax
| 42.924 | 102.735 | 227.252 | 81.246 | 46.197 | 68.89 | 99.759 | 110.639 | 120.753 | 99.233 | 58.514 | 77.647 | 97.857 | 88.762 | 67.648 | 54.991 |
| Income Before Tax Ratio
| 0.006 | 0.017 | 0.033 | 0.013 | 0.014 | 0.021 | 0.029 | 0.038 | 0.048 | 0.045 | 0.026 | 0.05 | 0.076 | 0.076 | 0.077 | 0.072 |
| Income Tax Expense
| 8.333 | 16.061 | 9.32 | 17.558 | 11.378 | 5.623 | 14.789 | 19.981 | 24.057 | 17.791 | 10.602 | 13.188 | 15.579 | 15.868 | 10.369 | 8.288 |
| Net Income
| 33.348 | 89.064 | 187.064 | 58.188 | 38.527 | 70.578 | 92.265 | 96.79 | 90.793 | 77.528 | 48.607 | 64.302 | 82.279 | 72.894 | 57.279 | 46.703 |
| Net Income Ratio
| 0.004 | 0.014 | 0.027 | 0.009 | 0.012 | 0.021 | 0.027 | 0.033 | 0.036 | 0.035 | 0.022 | 0.042 | 0.064 | 0.063 | 0.065 | 0.061 |
| EPS
| 0.06 | 0.15 | 0.32 | 0.097 | 0.066 | 0.12 | 0.16 | 0.17 | 0.16 | 0.16 | 0.096 | 0.13 | 0.18 | 0.2 | 0.15 | 0.15 |
| EPS Diluted
| 0.06 | 0.15 | 0.32 | 0.097 | 0.066 | 0.12 | 0.16 | 0.17 | 0.16 | 0.16 | 0.096 | 0.13 | 0.18 | 0.2 | 0.15 | 0.15 |
| EBITDA
| 178.196 | 234.968 | 368.86 | 176.712 | 162.253 | 205.058 | 148.484 | 157.382 | 180.408 | 145.172 | 99.03 | 108.184 | 121.736 | 107.862 | 81.572 | 67.956 |
| EBITDA Ratio
| 0.023 | 0.038 | 0.054 | 0.028 | 0.049 | 0.061 | 0.044 | 0.054 | 0.072 | 0.066 | 0.044 | 0.07 | 0.095 | 0.093 | 0.092 | 0.089 |